Margrethe Vestager, executive vice-president of the European Commission, said Aspen’s drugs would still be used by thousands of patientsA South African drug company will cut the price of cancer drugs in the UK and other European countries by nearly 75 per cent after Brussels took action over alleged price gouging. Aspen Pharmacare bought the rights to five off-patent cancer medicines — one of which comes in both liquid and tablet form — from GlaxoSmithKline in 2009 and imposed large price increases in many European markets. The Times has previously revealed how Aspen threatened to stop supplying the drugs in an effort to force some health systems to comply, while in the UK the price of a leukaemia treatment rose from £5.20 to about £65 a pack. SponsoredThe European Commission yesterday announced it would accept a deal offered by the company to cut the

Source: The Times February 11, 2021 18:00 UTC